-
公开(公告)号:US20180044391A1
公开(公告)日:2018-02-15
申请号:US15556282
申请日:2016-03-07
Inventor: Jung GUNDRAM , Helmut SALIH , Cornelia LINDNER , Berit LOCHMANN
CPC classification number: C07K14/5443 , A61K38/00 , C07K16/2803 , C07K16/3069 , C07K2317/41 , C07K2317/526 , C07K2317/72 , C07K2317/732 , C07K2319/00 , C07K2319/33 , C07K2319/74 , C07K2319/75
Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.
-
公开(公告)号:US20180042963A1
公开(公告)日:2018-02-15
申请号:US15801133
申请日:2017-11-01
Applicant: The Regents of the University of California
Inventor: Chia-Yung Wu , James Onuffer , Wendell A. Lim
IPC: C07K14/705 , C07K16/28 , C12N9/14 , C12N5/0783 , C07K16/18 , C07K14/725 , C12N9/90 , A61K39/00
CPC classification number: A61K35/17 , A61K47/6891 , A61K2039/505 , C07K14/705 , C07K14/7051 , C07K14/70521 , C07K14/70575 , C07K14/70578 , C07K16/18 , C07K16/2803 , C07K16/2866 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/20 , C07K2319/33 , C07K2319/74 , C12N5/0636 , C12N9/14 , C12N9/90 , C12N2510/00 , C12Y502/01008
Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
-
公开(公告)号:US09880151B2
公开(公告)日:2018-01-30
申请号:US14112512
申请日:2012-05-23
Applicant: Paul Michael Watt , Richard Hopkins , Katrin Hoffman
Inventor: Paul Michael Watt , Richard Hopkins , Katrin Hoffman
CPC classification number: G01N33/5014 , C07K14/4723 , C07K2319/00 , C07K2319/74 , C12N2503/02 , C40B60/12
Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.
-
公开(公告)号:US09878048B2
公开(公告)日:2018-01-30
申请号:US15232714
申请日:2016-08-09
Inventor: Jeffrey A. Hubbell , Stephan Kontos , Karen Y. Dane
IPC: C07K16/28 , C07K14/705 , A61K39/008 , A61K47/48 , A61K9/107 , A61K9/51 , A61K39/00 , C07K7/08 , C07K16/18 , C07K14/62 , C07K14/74 , C12N9/82 , C12N9/96 , A61K38/00
CPC classification number: A61K47/6811 , A61K9/1075 , A61K9/513 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/64 , A61K47/6803 , A61K47/6815 , A61K47/6843 , A61K47/6849 , A61K2039/6031 , A61K2039/605 , A61K2039/6056 , C07K7/08 , C07K14/62 , C07K14/70539 , C07K16/18 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/30 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , C12N9/82 , C12N9/96 , C12Y305/01001
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
-
45.
公开(公告)号:US20170369551A1
公开(公告)日:2017-12-28
申请号:US15632257
申请日:2017-06-23
Applicant: ANTHERA PHARMACEUTICALS, INC.
Inventor: Renee MARTIN , James PENNINGTON , Colin HISLOP , Charles OLSON
IPC: C07K14/705 , A61K38/17 , A61K45/06
CPC classification number: C07K14/70575 , A61K38/177 , A61K45/06 , A61P13/12 , C07K2319/31 , C07K2319/74
Abstract: Provided herein are methods, compositions, and kits for treating IgA nephropathy and Henoch-Schönlein purpura nephritis using BAFF inhibitors, including blisibimod.
-
公开(公告)号:US09850293B2
公开(公告)日:2017-12-26
申请号:US14678972
申请日:2015-04-04
Applicant: CEDARS-SINAI MEDICAL CENTER
Inventor: Lali K. Medina-Kauwe , Jessica Sims , Michael Taguaim , Chris Hanson , Xiaojiang Cui
IPC: A61K38/00 , C07K14/475 , A61K31/517 , A61K31/704 , A61K38/18 , A61K31/713 , C12N15/87 , A61K47/62 , A61K47/68 , A61K39/00 , A61K48/00
CPC classification number: C07K14/4756 , A61K31/517 , A61K31/704 , A61K31/713 , A61K38/00 , A61K38/1883 , A61K39/0011 , A61K47/62 , A61K47/6855 , A61K48/00 , C07K2319/10 , C07K2319/33 , C07K2319/74 , C07K2319/80 , C12N15/87
Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence.
-
47.
公开(公告)号:US20170362299A1
公开(公告)日:2017-12-21
申请号:US15532770
申请日:2015-12-08
Applicant: 1GLOBE BIOMEDICAL CO., LTD.
Inventor: CHIANG J. LI , SHYAM UNNIRAMAN
IPC: C07K14/735 , C07K16/28 , A61K38/00
CPC classification number: C07K14/70535 , A61K38/00 , A61K2039/505 , C07K16/2806 , C07K16/2809 , C07K16/46 , C07K2317/24 , C07K2317/622 , C07K2317/732 , C07K2317/92 , C07K2319/00 , C07K2319/74
Abstract: Novel synthetic biology-based ADCC technologies are provided that enhance or enable ADCC responses, for example, through a rationally-designed soluble universal ADCC enhancer protein (SUAEP) where a high-affinity CD3-binding domain is fused to a high-affinity Fc-binding domain. The SUAEP technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
-
48.
公开(公告)号:US20170333481A1
公开(公告)日:2017-11-23
申请号:US15607059
申请日:2017-05-26
Applicant: Precision BioSciences, Inc.
Inventor: Derek Jantz , James Jefferson Smith , Michael G. Nicholson , Daniel T. MacLeod , Victor Bartsevich , Jeyaraj Antony
IPC: A61K35/17 , C12N15/113 , A61K39/00 , C12N15/86 , C12N15/09 , C12N5/0783
CPC classification number: A61K35/17 , A61K39/0011 , A61K48/0008 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K14/70503 , C07K14/7051 , C07K16/2803 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2319/01 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C07K2319/40 , C07K2319/74 , C12N5/0636 , C12N15/09 , C12N15/113 , C12N15/86 , C12N2510/00
Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
-
公开(公告)号:US20170327556A1
公开(公告)日:2017-11-16
申请号:US15399138
申请日:2017-01-05
Applicant: Merrimack Pharmaceuticals, Inc.
Inventor: Emily FLORINE , Dmitri B. KIRPOTIN , Paul KOPESKY , Alexey Alexandrovich LUGOVSKOY , Rachel RENNARD , Birgit M. SCHOEBERL
IPC: C07K14/65 , C07K14/47 , A61K38/30 , A61K9/00 , A61K31/573 , A61K9/50 , A61K9/127 , A61K38/17 , A61K38/00
CPC classification number: C07K14/65 , A61K9/0019 , A61K9/0024 , A61K9/127 , A61K9/5015 , A61K31/573 , A61K38/00 , A61K38/1709 , A61K38/30 , C07K14/47 , C07K2319/74 , A61K2300/00
Abstract: Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided.
-
公开(公告)号:US09814780B2
公开(公告)日:2017-11-14
申请号:US15232694
申请日:2016-08-09
Inventor: Jeffrey A. Hubbell , Stephan Kontos , Karen Y. Dane
IPC: A61K38/00 , A61K47/48 , A61K9/107 , A61K9/51 , A61K39/00 , C07K7/08 , C07K16/18 , C07K14/62 , C07K14/74 , C12N9/82 , C07K16/28 , C12N9/96
CPC classification number: A61K47/6811 , A61K9/1075 , A61K9/513 , A61K38/00 , A61K39/0008 , A61K39/001 , A61K47/64 , A61K47/6803 , A61K47/6815 , A61K47/6843 , A61K47/6849 , A61K2039/6031 , A61K2039/605 , A61K2039/6056 , C07K7/08 , C07K14/62 , C07K14/70539 , C07K16/18 , C07K16/28 , C07K2317/56 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/30 , C07K2319/33 , C07K2319/41 , C07K2319/43 , C07K2319/74 , C12N9/82 , C12N9/96 , C12Y305/01001
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.